- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.04. | ImageneBio $30 Million Private Placement Ignites Stock | 1 | Benzinga.com | ||
| 13.04. | ImageneBio stock jumps on $30M financing | 1 | Seeking Alpha | ||
| 13.04. | ImageneBio: 30 Millionen US-Dollar für Medikament gegen Haarausfall und Dermatitis | 1 | Investing.com Deutsch | ||
| 13.04. | ImageneBio, Inc.: ImageneBio Announces $30 Million Private Placement | 1 | GlobeNewswire (USA) | ||
| 13.04. | ImageneBio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 17.03. | ImageneBio, Inc.: ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 10.03. | ImageneBio, Inc. GAAP EPS of -$9.64 | 1 | Seeking Alpha | ||
| 10.03. | ImageneBio, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| IMAGENEBIO Aktie jetzt für 0€ handeln | |||||
| 10.03. | ImageneBio, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 10.03. | ImageneBio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.02. | ImageneBio appoints Dr. Porter-Brown as Chief Medical Officer | 1 | Investing.com | ||
| 10.02. | ImageneBio, Inc.: ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer | 1.006 | GlobeNewswire (Europe) | Brings 20+ years of clinical development experience in autoimmune and inflammatory diseases, including OX40/OX40L program leadership Will build and lead Imagene's clinical organization and drive completion... ► Artikel lesen | |
| 18.12.25 | ImageneBio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 25.11.25 | ImageneBio: Wedbush startet Coverage mit negativem Votum und Kursziel 2 US-Dollar | 2 | Investing.com Deutsch | ||
| 25.11.25 | Wedbush assumes coverage of ImageneBio stock with Underperform rating | 2 | Investing.com | ||
| 19.11.25 | ImageneBio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 12.11.25 | ImageneBio, Inc. GAAP EPS of -$2.91 | 1 | Seeking Alpha | ||
| 12.11.25 | ImageneBio, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 12.11.25 | ImageneBio, Inc.: ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team | 504 | GlobeNewswire (Europe) | $142.6 million cash and cash equivalents and marketable securities as of September 30, 2025 Protocol amendment for ongoing Phase 2b ADAPTIVE study of IMG-007 in atopic dermatitis (AD) announced to... ► Artikel lesen | |
| 12.11.25 | ImageneBio, Inc. - 10-Q, Quarterly Report | - | SEC Filings |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 5,005 | -2,63 % | Evotec-Aktie mit +46% - kommt das Comeback? | Die Evotec-Aktie hat zuletzt kräftig zugelegt und stieg um rund +46% an. Damit hat sich das Chartbild deutlich verbessert und eine mögliche Trendwende rückt in den Fokus. Nach der dynamischen Rallye... ► Artikel lesen | |
| BIOGEN | 166,48 | +6,34 % | Ihre wichtigsten Termine: Alphabet, Meta, Microsoft, Amazon, Ebay, Biogen & Mercedes-Benz legen Zahlen vor | © Foto: Dall-EGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 06:45 Uhr, Schweiz:... ► Artikel lesen | |
| VIKING THERAPEUTICS | 26,800 | -3,07 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 | 78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 Diabetes
SAN DIEGO, March 26, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking)... ► Artikel lesen | |
| MAINZ BIOMED | 0,450 | -9,64 % | Quantum Cyber N.V. - 8-K, Current Report | ||
| TREVENA | 4,000 | +1.983 % | TREVENA INC - 8-K, Current Report | ||
| ABIVAX | 94,10 | -1,10 % | EQS-News: ABIVAX: Abivax to Present Data on Obefazimod at Digestive Disease Week | EQS-News: ABIVAX
/ Key word(s): Conference
Abivax to Present Data on Obefazimod at Digestive Disease Week
22.04.2026 / 22:05 CET/CEST
The issuer is solely responsible... ► Artikel lesen | |
| GALAPAGOS NV | 24,020 | -1,07 % | Galapagos NV: Galapagos' Shareholders Adopt All Resolutions Proposed by the Board of Directors at the Annual and Extraordinary Shareholders' Meetings 2026 | Mechelen, Belgium; April 28, 2026, 22:01 CET - Galapagos NV (Euronext & NASDAQ: GLPG) today announces that all resolutions proposed at the Company's Annual and Extraordinary Shareholders' Meetings (AGM... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 2,510 | -3,46 % | Cellectar Biosciences, Inc.: Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC) | FLORHAM PARK, N.J., April 14, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 1,398 | -2,85 % | Cardiff Oncology, Inc.: Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | ||
| COHERUS ONCOLOGY | 1,563 | +3,10 % | Coherus Oncology, Inc.: Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update | - LOQTORZI net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 - - Reduced secured and convertible debt by 90% from $480 million to $38.8 million over 2024-2025 - - $172.1... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 3,536 | +0,37 % | CytomX-Aktie: sharedealsPlus-Highflyer schießt auf +1.835% Kursgewinn | Die Aktie von CytomX Therapeutics gehört weiterhin zu den spektakulärsten Turnaround-Stories im Biotech-Sektor. Seit ihrem Vorjahrestief hat sich der Kurs des sharedealsPlus-Tipps inzwischen um rund... ► Artikel lesen | |
| CYTOKINETICS | 51,14 | -1,27 % | Cytokinetics stellt neue Daten zu Herzmedikament Aficamten auf Fachkongress vor | ||
| SENSEI BIOTHERAPEUTICS | 27,030 | -7,15 % | Healthcare & Biotech Stocks Rally After Hours: Sensei, Praxis, Cooper, Vanda, Cue, ResMed | WASHINGTON (dpa-AFX) - Several healthcare and biotech names posted notable gains in Thursday's after-hours session, driven by clinical updates, earnings results, and regulatory developments.Sensei... ► Artikel lesen | |
| REGENXBIO | 7,252 | -2,13 % | Bronstein, Gewirtz & Grossman, LLC: Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm | New York, New York--(Newsfile Corp. - April 14, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed... ► Artikel lesen | |
| BIOAGE LABS | 14,340 | -3,76 % | BioAge Labs, Inc.: BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP | 120 mg and newly announced 60 mg once-daily doses each achieved =85% median hsCRP reductions in participants with obesity and elevated baseline inflammation BGE-102 was well tolerated across all dose... ► Artikel lesen |
IMAGENEBIO INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 5,790 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IMAGENEBIO INC finden Sie auf Wallstreet Online.